Ill. Appeals Court Refuses to Reinstate Lupron ‘Off Label’ Action Against Abbott Labs



DOCUMENTS
  • Opinion


CHICAGO — An Illinois appeals court has refused to reinstate a lawsuit against Abbott Laboratories Inc. involving its endometriosis drug Lupron, finding the plaintiff failed to present “newly discovered evidence” addressing the adequacy of the drug’s warnings.

In a March 30 opinion, the Illinois Court of Appeals, 1st District, explained that the plaintiff’s expert testimony does not undermine the trial court’s independent conclusion that the Lupron warning was adequate as a matter of law.

In 2012, Iwona Johnson sought treatment at a Chicago hospital for heavy menstrual bleeding. She was prescribed Lupron, which is FDA-approved to treat endometriosis. However, the …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS